Etelcalcetide HCl manufacturers
|
| | Etelcalcetide HCl Basic information |
| Product Name: | Etelcalcetide HCl | | Synonyms: | Etelcalcetide HCl;Etelcalcetide Hydrochloride (AMG-416);AMG416;KAI-4169;AMG 416;AMG 416 hydrochloride;KAI-4169 hydrochloride;Etelcalcetide hydrochloride,KAI-4169,AMG416,KAI4169,CaSR,KAI 4169,AMG 416,inhibit,Etelcalcetide,AMG-416,Inhibitor,Calcium-sensing receptor | | CAS: | 1334237-71-6 | | MF: | C38H74ClN21O10S2 | | MW: | 1084.71186 | | EINECS: | | | Product Categories: | | | Mol File: | 1334237-71-6.mol |  |
| | Etelcalcetide HCl Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO:10.0(Max Conc. mg/mL);8.37(Max Conc. mM)
PBS (pH 7.2):10.0(Max Conc. mg/mL);8.37(Max Conc. mM)
Water:50.0(Max Conc. mg/mL);41.87(Max Conc. mM) | | form | A crystalline solid | | color | White to off-white | | Sequence | Ac-d-Cys（Cys）-d-Ala-d-Arg-d-Arg-d-Arg-d-Ala-d-Arg-NH2 (Disulfide bridge: Cys-Cys) | | InChIKey | CRSDUYHPKJMYMG-KZTORMJDNA-N |
| | Etelcalcetide HCl Usage And Synthesis |
| Uses | Etelcalcetide hydrochloride (AMG 416 hydrochloride; KAI-4169 hydrochloride) is a synthetic calcimimetic as an activator of the calcium sensing receptor (CaSR). Etelcalcetide hydrochloride is effective in lowering parathyroid hormone (PTH) concentrations in patients receiving dialysis with secondary hyperparathyroidism receiving hemodialysis, which is promising for research in the field of secondary hyperparathyroidism and chronic kidney disease[1][2]. | | in vivo | Etelcalcetide hydrochloride (2.5 μg/h and 20 μg/h, infusion, 3 days) significantly reduces plasma PTH concentrations and decreased the renal expression of Cyp24a1 with a higher delivery rate[1]. | Animal Model: | C57BL7/6J male mice | | Dosage: | 2.5 μg/h and 20 μg/h | | Administration: | infusion, 3 days | | Result: | Significantly reduced plasma PTH concentrations and unaltered Cldn14 expression with 2.5 μg/h, but decreased the renal expression of Cyp24a1 with 20 μg/h [1] |
| | References | [1] Differential parathyroid and kidney Ca2+-sensing receptor activation in autosomal dominant hypocalcemia 1 DOI:10.1016/j.ebiom.2022.103947
[2] Fujioka A, et al. Effect of etelcalcetide on parathyroid hormone secretion by primary hyperparathyroidism patient-derived primary parathyroid cells[J]. J Bone Miner Metab. 2021 May;39(3):396-403. DOI:10.1007/s00774-020-01158-2 |
| | Etelcalcetide HCl Preparation Products And Raw materials |
|